Krsnaa Diagnostics Ltd

Krsnaa Diagnostics Ltd’s shares declined sharply to a fresh 52-week low of Rs.581 on 9 Mar 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its recent financial performance and investor participation.

Krsnaa Diagnostics Ltd’s stock declined to a fresh 52-week low of Rs.617.4 today, marking a significant price level amid continued downward momentum. The stock has underperformed its sector and broader market indices, reflecting a series of financial and market-related factors influencing its valuation.

Krsnaa Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 03 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Krsnaa Diagnostics Ltd, a key player in the Healthcare Services sector, has reached a new 52-week low of Rs.620.35, marking a significant decline in its stock price amid a challenging market environment. The stock’s recent performance reflects a continuation of downward momentum, with notable financial and market factors contributing to this development.

Krsnaa Diagnostics Ltd, a player in the healthcare services sector, has touched a fresh 52-week low of Rs.621.3 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting a challenging period for the company’s share price.

Krsnaa Diagnostics Ltd’s share price declined to a fresh 52-week low of Rs.626.15 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a series of financial and market pressures that have weighed on investor sentiment over the past year.

Krsnaa Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis below reflects the stock's current position as of 20 February 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.

Krsnaa Diagnostics Ltd has witnessed a notable improvement in its valuation parameters, shifting from an attractive to a very attractive rating. This change reflects a significant recalibration in price-to-earnings and price-to-book value metrics relative to its historical averages and peer group, suggesting a more compelling entry point for investors despite recent stock underperformance.

Krsnaa Diagnostics Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 6 February 2026, reflecting a nuanced shift in its financial quality and valuation metrics despite ongoing challenges in its quarterly financial performance and market returns. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this change, providing investors with a comprehensive understanding of the company’s current standing within the healthcare services sector.

Krsnaa Diagnostics Ltd has seen its quality rating upgraded from average to good, reflecting notable improvements in its business fundamentals. This shift comes amid a challenging market backdrop where the stock has underperformed the Sensex over the past year but outpaced it over the medium term. Investors should carefully analyse the company’s enhanced return ratios, debt metrics, and operational consistency to understand the implications of this upgrade.

Krsnaa Diagnostics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.

Krsnaa Diagnostics Ltd commenced trading today with a pronounced gap down, opening 5.18% lower than its previous close, reflecting heightened market apprehension following recent developments. The stock’s weak start underscores ongoing pressures within the healthcare services sector, as investors reacted to overnight news and technical indicators signalling caution.

Krsnaa Diagnostics Ltd., a healthcare services provider with a market capitalisation of ₹2,169.00 crores, reported a concerning performance in Q3 FY26 (October-December 2025), with consolidated net profit declining sharply to ₹15.25 crores—a sequential drop of 36.33% from Q2 FY26's ₹23.95 crores and a year-on-year decline of 21.47% from ₹19.42 crores in Q3 FY25. The disappointing results triggered a negative market reaction, with the stock trading at ₹665.00 as of February 13, 2026, down 1.55% on the day and reflecting broader weakness with the stock now 25.43% below its 52-week high of ₹891.80.

Krsnaa Diagnostics Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting evolving market perceptions and underlying financial metrics. Despite a challenging sector backdrop and mixed returns relative to the Sensex, the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point for discerning investors seeking exposure to healthcare services.

Krsnaa Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.